{"id":585623,"date":"2022-02-08T19:46:01","date_gmt":"2022-02-08T19:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=585623"},"modified":"2022-02-08T19:46:01","modified_gmt":"2022-02-08T19:46:01","slug":"chronic-neuropathic-pain-market-to-accelerate-substantially-during-the-forecast-period-delveinsight-key-companies-medincell-kineta-pfizer-algiax-centrexion-therapeutics-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-neuropathic-pain-market-to-accelerate-substantially-during-the-forecast-period-delveinsight-key-companies-medincell-kineta-pfizer-algiax-centrexion-therapeutics-and-others_585623.html","title":{"rendered":"Chronic Neuropathic Pain Market to Accelerate Substantially During the Forecast Period – DelveInsight | Key Companies – MedinCell, Kineta, Pfizer, Algiax, Centrexion Therapeutics, and Others"},"content":{"rendered":"
\n
\"Chronic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Chronic Neuropathic Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Chronic Neuropathic Pain Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Chronic Neuropathic Pain market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032.<\/p>\n

It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Chronic<\/p>\n

Chronic Neuropathic Pain: An Overview<\/strong><\/p>\n

Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibers and central neurons, and affects 7–10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the aging global population, increased incidence of diabetes mellitus, and improved survival from cancer after chemotherapy.<\/em><\/p>\n

All neuropathic pain that is labeled as chronic has a history of an acute phase, that is, before the first 3 months have elapsed, a timeline agreed upon by the International Association for the Study of Pain and the WHO.<\/em><\/p>\n

The treatment initially focuses on resolving the underlying cause. Medications used to treat neuropathic pain include over-the-counter analgesics, anticonvulsants, tricyclic antidepressants (TCAs), topical anesthetic agents, nonsteroidal anti-inflammatory drugs (NSAIDs), antiarrhythmics, narcotic analgesics, and opioids.<\/em><\/strong><\/p>\n

Chronic Neuropathic Pain Market Key Facts<\/strong><\/p>\n